7th International Workshop on Clinical Pharmacology of HIV Therapy Lisbon,, Portugal April 20-22, 22, 2006
|
|
- Zoe Little
- 6 years ago
- Views:
Transcription
1 7th International Workshop on Clinical Pharmacology of HIV Therapy Lisbon,, Portugal April 20-22, 22, 2006 Nancy Sheehan, B.Pharm, M.Sc Immunodeficiency Service, Montréal Chest Institute Faculté de Pharmacie, Université de Montréal
2
3 Conference Content Clinical Pharmacology in Developing Countries Therapeutic Drug Monitoring PK in special populations Pharmacogenetics CNS & Genital Tract Penetration Drug-Drug interactions PK / PD of existing and new drugs FDA roundtable: Antiretroviral Drug Labelling and Drug Interaction
4 Angela Kashuba, 7th PK workshop, Lisbon, April 21, 2006
5 Angela Kashuba, 7th PK workshop, Lisbon, April 21, 2006
6 Target Minimal Concentrations ARV Cmin (mg/l) Naïve pts Éfavirenz 1.0 Névirapine Amprénavir Atazanavir 0.15 Indinavir Lopinavir Nelfinavir Ritonavir Saquinavir Cmin (mg/l) PI experienced pts NA NA GIQ NA NA
7 Poster and Oral Abstracts Inhibitory Quotients PK in special populations: Pediatrics Drug drug interactions Enfuvirtide interactions Tipranavir interactions Acid-modifying agent interactions Interactions via P-glycoproteinP
8
9 Poster and Oral Abstracts Inhibitory Quotients PK in special populations: Pediatrics Drug drug interactions Enfuvirtide interactions Tipranavir interactions Acid-modifying agent interactions Interactions via P-glycoprotein
10 Tipranavir Genotypic Inhibitory Quotient Predicts Virological Response at 24 weeks to TPV-based Salvage Regimens S Bonora,, D Gonzalez de Requena,, A Calcagno,, M Milia, A D AvolioD Avolio,, M Sciandra,, S Garazzino,, M Siccardi,, A. Sinicco,, G Di Perri Abstract 83
11 TPV GIQ Methods 24 week PK/PD study 2 NRTIs + TPV/RTV ± T-20 Ctrough wk 2,4,8,12, 24 GIQ = mean Ctrough # TPV mutations (Valdez et al, 3rd IAS) Virologic Response: Viral load < 50 copies / ml and/or > 1 log drop Bonora et al, 7th PK Workshop, Abstract 83.
12 TPV GIQ Results: Logistic Regressions Wk 24 Parameter OR CI 95% p value Ctrough # TPV mutations TPV GIQ T Baseline VL Bonora et al, 7th PK Workshop, Abstract 83.
13 TPV GIQ Target > ng/ml %Virologic Response GIQ < GIQ > Bonora et al, 7th PK Workshop, Abstract 83.
14 Genotypic Inhibitory Quotient as Best PK/PD Predictor of Virologic Response to a LPV/SQV dual RTV- boosted regimen in patients with multiresistant HIV-1 S Lam, MS Delisle, L Labbé,, GHR Smith, CJL la Porte, DM Burger, RG Lalonde, NL Sheehan Abstract 81
15 Logistic binary regressions for viral load < 400 copies/ml at week 48 vs PK / PD parameters PK / PD parameter p value LPV C SQV C LPV GIQ 0.049* SQV GIQ SQV mgiq GIQ 0.044* Multivariate analysis: age, gender, baseline CD4 and viral load, weight, and # ARV in regimen had no impact on significance of LPV GIQ and GIQ
16 Virologic response as a function of LPV, SQV and GIQ % subjects with viral load < 400 copies/ml LPV GIQ SQV GIQ Sum GIQ GIQ targets > 1.7 > 0.35 > 2.6 Below Target Above Target P value Fisher s Exact Test
17 Poster and Oral Abstracts Inhibitory Quotients PK in special populations: Pediatrics Drug drug interactions Enfuvirtide interactions Tipranavir interactions Acid-modifying agent interactions Interactions via P-glycoprotein
18 An audit of TDM in paediatric subjects from the UK and Ireland S Gibbons, D Back, S Khoo Abstract 8
19 % Concentrations Below Adult Targets LPV EFV NVP Infants 16,7-44,4 1 5 years 19,4 25,9 22, years 19,0 19,5 20,9 Adolescents 25,5 26,8 21,4 Gibbons et al, 7th PK Workshop, Abstract 8.
20 % Concentrations < LOQ Lopinavir Nevirapine Infants 8,3 4,4 1 5 years 15,1 6, years 17 9,3 Adolescents 19,4 10,7 Gibbons et al, 7th PK Workshop, Abstract 8.
21 Age-dependent PK of 3TC in HIV-infected children DM Burger, G Verweel,, C Verwey-Van Van Wissen,, CJL la Porte, A, Bergshoeff,, H. Lyall, N. Hartwig,, H. Green, D. Gibb,, R. De Groot Abstract 20
22 PK variability with age of 3TC dosed 4 mg/kg PK Parameter Pts 6 years vs > 6 AUC 42 % Cmax 51 % CL 74% VD 109 % T 1/2 Comparable Burger et al, 7th PK Workshop, Abstract 20
23 Poster and Oral Abstracts Inhibitory Quotients PK in special populations: Pediatrics Drug drug interactions Enfuvirtide interactions Tipranavir interactions Acid-modifying agent interactions Interactions via P-glycoprotein
24 Unexpected drug-drug interaction between TPV/rtv and enfuvirtide D Gonzalez de Requena,, A Calagno,, S. Bonora,, L. Ladetto,, A. D AvolioD Avolio,, M. Sciandra, M. Siccardi,, O. Bargiacchi,, A. Sinicco,, G. Di Perri Abstract 52
25 TPV & T-20T TPV Pk samples taken hours post- dose N = 55 with 463 random samples PK model: 1st order absorption and elimination, monocompartmental Gonzalez de Requena et al, 7th PK Workshop, Abstract 52
26 Tipranavir PK C trough (ng/ml) With T-20 Without T ± ± Vd / F (L) Kel (1/h) T ½ (h) Gonzalez de Requena et al, 7th PK Workshop, Abstract 52
27 PK evaluation of potential interaction between tipranavir and enfuvirtide A Curran,, R Lopez, L Pou, C Azuaje,, E Ribera, A Pahissa Abstract 53
28 Tipranavir & T-20T Intensive PK study (12 hours) N = 8 with TPV & T-20 T vs 4 without T-20 Total: 44 C troughs Curran et al, 7th PK Workshop, Abstract 53
29 Tipranavir PK median,, (IQR) PK Parameter C trough T-20T Without T-20 ( ) AUC ( ) ) Cmax ( ) 137.9) 39.5 ( ) 695 ( ) 81.9 ( ) p value Curran et al, 7th PK Workshop, Abstract 53
30 Absence of an interaction between the potent HIV PI TMC114 and the FI enfuvirtide in the Power 3 analysis V Sekar,, E De Paepe, T Vangeneugden,, R Falcon, E Lefebvre, R Hoetelmans Abstract 54
31 TMC-114 PK & T-20T Median (range) With T-20 Without T-20 AUC (ng*h/ml) ( ) ( ) C trough (ng/ml) ( ) 10919) ( ) Sekar et al, 7th PK Workshop, Abstract 54
32 Poster and Oral Abstracts Inhibitory Quotients PK in special populations: Pediatrics Drug drug interactions Enfuvirtide interactions Tipranavir interactions Acid-modifying agent interactions Interactions via P-glycoproteinP
33 The PK Interaction Between ATZ/r and TPV/r in healthy volunteers JP Sabo,, M Elgadi,, J Wruck,, W Cameron, TR MacGregor,, M Kraft, H Valdez, D Mayers Abstract 41
34 TAZ & TPV Methods Day 1 Day9 Day 16 Day 24 Day 33 TPV TAZ PK PK TAZ PK PK Steady-state intensive PK study in healthy volunteers N = 21 TPV 500 / rtv 200 BID; TAZ 300 / rtv 100 QD Sabo et al, 7th PK Workshop, Abstract 41
35 TAZ PK with TPV GMR, 90% CI PK Parameter % change GMR (90% CI) AUC ( ) 0.36) Cmax ( ) 0.5) Cmin ( ) 0.24) Sabo et al, 7th PK Workshop, Abstract 41
36 TPV PK with TAZ GMR, 90% CI PK Parameter % change GMR (90% CI) AUC ( ) 1.32) Cmax ( ) Cmin ( ) Sabo et al, 7th PK Workshop, Abstract 41
37 Stereoselective PK of methadone after coadministration with steady- state TPV/rtv in healthy volunteers JP Sabo,, S Macha, C Oksala,, C Edwards, P Jones, TR MacGregor,, H Valdez, D Mayers
38 TPV & Methadone Methods Day 1 Day 9 TPV PK M 5 mg M 5 mg PK Steady-state intensive PK study in healthy volunteers N = 15 healthy volunteers TPV 500 / rtv 200 BID; 2 single doses of methadone 5 mg (Day 1 and 9) Sabo et al, 7th PK Workshop, Abstract 42
39 TPV & Methadone GMR, 90% CI, % Change PK Parameter AUC0-24 (ng*h/ml) S- methadone (inactive) 0.37 ( ) 0.41) - 63 % R-methadone (active) 0.52 ( ) 0.56) - 48 % Cmax (ng/ml) 0.38 ( ) 0.43) - 62 % 0.54 ( ) 0.58) - 46 % Sabo et al, 7th PK Workshop, Abstract 42
40 Poster and Oral Abstracts Inhibitory Quotients PK in special populations: Pediatrics Drug drug interactions Enfuvirtide interactions Tipranavir interactions Acid-modifying agent interactions Interactions via P-glycoproteinP
41 Steady-state PK of QD fosamprenavir / ritonavir and atazanavir / ritonavir alone and in combination with 20 mg QD of omeprazole in healthy volunteers A Luber,, R Brower, C Peloquin,, I Frank Abstract 36
42 Steady-state PK of fapv/rtv 1400 / 200 QD and TAZ/rtv 300/100 with Omeprazole 20 mg Open-label cross-over over interaction study PK PK PK PK Regimen 1 + OMP WASHOUT Regimen 2 + OMP Study Day Luber et al, Poster 36, 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, 2006
43 Impact of omeparazole 20 mg on steady-state pharmacokinetics of fosamprenavir and atazanavir Concentrations ( u g FAPV / RTV FAPV / RTV + OMP TAZ / RTV TAZ /RTV + OMP Hours post - dose Atazanavir Cmin and AUC decreased by 27% Luber et al, Poster 36, 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, 2006
44 Poster and Oral Abstracts Inhibitory Quotients PK in special populations: Pediatrics Drug drug interactions Enfuvirtide interactions Tipranavir interactions Acid-modifying agent interactions Interactions via P-glycoproteinP
45
46
47 The ABC transporter P-P glycoprotein is inhibited by LPV and low-dose ritonavir both in HIV-infected patients and healthy volunteers A Jetter,, U Fuhr,, R Aarnoutse,, A Lazar,, F Abdulrazik,, N Schmeisser,, E Schomig,, D Burger, G Fatkenheuer,, C Wyen Abstract 37
48 LPV/rtv & p-glycoproteinp Methods N = 30, HIV positive ARV naive patients Intensive PK before LPV / rtv and 14 days post LPV/rtv 400 BID Probes: 0.5 mg digoxin Dextromethorphan Midazolam Jetter et al, 7th PK Workshop, Abstract 37
49 In patients: Digoxine AUC 0-24 : 81 % (90%CI: 56% - 109%) Jetter et al, 7th PK Workshop, Abstract 37
50 Jetter et al, 7th PK Workshop, Abstract 37
51 Effect of MDR proteins 2 and 4 polymorphisms on TNF PK in HIV-infected patients J Kiser,, C Aquilante, P Anderson, P Wolfe, M Carten,, C Fletcher Abstract 34
52 TNF and MDR2, MDR4 TNF potentially substrate MDR2 and MDR4 N = / 27 + LPV/ rtv 6 / 37 black Genotype MRP2 SNPs (G1249A, C-24T) C MRP4 SNPs (A3463G, T4131G) Frequency G1249A: 22.2 % C-24T: 16.7 % A3463G: 20.4 % T4131G: 40.7%
53 MRP4 A3463G Intracell TNF conc. TNF AUC TNF CLr MRP2 C-24T TNF fraction excreted AA CC AG / GG CT 31 % 37% IC TNF conc: fmol/10 6 cells; AUC mcg*h/ml; CLr: L/h
54 Questions?
Pharmacology Update Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005
Pharmacology Update 2005 Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005 I m having a Maalox moment!!! Gastric Hypoacidity in HIV 20% incidence in HIV (unrelated to CD 4 ) Antacids, ddi tablets, H2-blockers
More informationClinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline
Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline Kirk Bertelsen, PhD Clinical Pharmacology Janssen Pharmaceuticals, Research & Development 4/24/2013 1 Incivo Simeprevir 2 Janssen
More informationTHERAPEUTIC DRUG MONITORING (TDM) Table 2. Dose Adjustment. Patient Drug (mg) Symptoms C trough -fold increase compared to MEC WT
1 The Sixth International Congress on Drug Therapy in HIV Infection took place in Glasgow, UK, on November 17-21, 2002. Pharmacological aspects of antiretroviral therapy were covered in both oral and poster
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationDrug-Drug Interactions that Matter
Perspective Drug-Drug Interactions that Matter It is increasingly difficult to keep track of information on drug-drug interactions in HIV therapeutics, and the clinical implications of much of the data
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More information13 th Conference on Retroviruses and Opportunistic Infections (CROI)
REPORT FROM 13 th Conference on Retroviruses and Opportunistic Infections (CROI) February 5 8, 5 2006 Denver, CO 1 Tipranavir Significantly Reduces Concentrations of Other ARVs -10 % change PK -30-50 -70-68
More informationFriday afternoon Programme
Friday afternoon Programme Pharmacology and TDM Dr Marta Boffito Consultant Physician, C&W Resistance to new anti-retrovirals Dr Steve Taylor Consultant Physician, Birmingham HIVPA Annual Conference 2008
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationPharmacokinetic Modelling of Antiretrovirals in HIV-Infected Patients
Pharmacokinetic Modelling of Antiretrovirals in HIV-Infected Patients Laura Dickinson NIHR Biomedical Research Centre, Royal Liverpool & Broadgreen University Hospital Trust & Department of Pharmacology,
More informationPhysiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters
Physiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters Qi Wang, Wenying Li, Ming Zheng, Timothy Eley, Frank
More informationTipranavir (TPV) Genotypic Inhibitory Quotient Predicts Virological Response at 48 Weeks to TPV-Based Salvage Regimens
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 28, p. 166 171 Vol. 52, No. 3 66-484/8/$8. doi:1.1128/aac.163-7 Copyright 28, American Society for Microbiology. All Rights Reserved. Tipranavir (TPV) Genotypic
More informationPharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2008.03220.x Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women Matthieu Roustit, 1,2 Malik Jlaiel, 1
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationThe advent of protease inhibitors (PIs) as PROCEEDINGS CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD
CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD ABSTRACT Tremendous strides were made in reducing the morbidity and mortality associated with HIV infection with
More informationTipranavir (TPV) genotypic Inhibitory Quotient (giq) predicts Virological Response at 48 weeks to TPV-based salvage regimens.
AAC Accepts, published online ahead of print on December 00 Antimicrob. Agents Chemother. doi:.1/aac.0-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationThe US Food and Drug Administration has
NEW ANTIRETROVIRAL AGENTS FOR TREATMENT-EXPERIENCED PATIENTS * Roy M. Gulick, MD, MPH ABSTRACT Antiretroviral treatment regimens currently available for the treatment of the human immunodeficiency virus
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationGeneric lopinavir/ritonavir is bioequivalent to Aluvia but neither result in adequate lopinavir exposure at 50% dose reduction: HIV-NAT 085
Generic lopinavir/ritonavir is bioequivalent to Aluvia but neither result in adequate lopinavir exposure at 50% dose reduction: HIV-NAT 085 Reshmie Ramautarsing, Meena Gorowara, Jasper van der Lugt, Jiratchaya
More informationARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting
ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting Dr. Andrew D Kambugu, FRCP (UK) Infectious Diseases Institute, Makerere University Outline of Discussion Key Definitions
More informationSupplementary information
Supplementary information Dose-response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs Lin Shen 1,2, Susan Peterson 1, Ahmad R. Sedaghat 1, Moira A. McMahon 1,2, Marc
More informationSelected Properties of Tipranavir. Aptivus, TPV, PNU Boehringer Ingelheim non-peptidic protease inhibitor
Selected Properties of Tipranavir Other names Aptivus, TPV, PNU-140690 Manufacturer Pharmacology/Mechanism of Action Molecular Weight 60.68 Activity Resistance - genotypic Resistance - phenotypic Cross-Resistance
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationDrug Interactions with ART and New TB drugs: What Do We Know?
Drug Interactions with ART and New TB drugs: What Do We Know? HIV/TB Research Frontiers Meeting 20 th Conference on Retroviruses and Opportunistic Infections 3 March 2013 Presented by: Kelly Dooley MD,
More informationSelected Properties of Fosamprenavir. Telzir, Lexiva (US), GW ViiV Healthcare ULC
Selected Properties of Fosamprenavir Other names Manufacturer Telzir, Lexiva (US), GW433-908 ViiV Healthcare ULC Pharmacology/Mechanism of Action Activity HIV aspartic protease is critical in the post-translational
More informationEvaluating an enhanced adherence intervention among HIV positive adolescents failing 2 nd line treatment
Evaluating an enhanced adherence intervention among HIV positive adolescents failing 2 nd line treatment Tariro D Chawana MBChB (UZ), MSc Clinical Pharmacology (UZ), DPhil student None Conflict of interest
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationLê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group
Lê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group 1 AP-HP, Hopital Bichat, Pharmacology-Toxicology, Paris, France, 2 IAME, UMR 1137,
More informationManagement of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationPharmacological determinants of long-term treatment success
Professor David Back Liverpool, UK Pharmacological determinants of long-term treatment success Pharmacological Issues with Antiretroviral Therapy Intrinsic potency Bioavailability Effect of food and other
More informationDrug Penetration to Sanctuary Sites Oral vs. IV Administration
Drug Penetration to Sanctuary Sites Oral vs. IV Administration Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious Diseases University
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationQuick Reference Guide to Antiretrovirals. Guide to Antiretroviral Agents
Author: Malte Schütz, MD June 1, 2002 Quick Reference Guide to Antiretrovirals Regular updates to this publication are posted on the Medscape Web site at http://hiv.medscape.com/updates/quickguide. Please
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationReferences: 1. XVI International AIDS Conference, 2006 Abstract no. ThPE0120 2. Bergshoeff A, Burger D, Farrelly L e t al. Pharmacokinetics of once daily vs. twice daily lamivudine and abacavir in HIV-Infected
More informationPharmacologic Characteristics and Delivery Options for Integrase Inhibitors
Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationComparison of GW (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG Changes (APV10013)
43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Poster A-1607 Comparison of GW433908 (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationDr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London.
BHIVA AUTUMN CONFERENCE 2010 Including CHIVA Parallel Sessions Dr Alan Winston Imperial College Healthcare NHS Trust London 7-8 October 2010, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationCombination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience
Antiviral Therapy 6: 201-229 Review Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience RPG van Heeswijk 1 *, AI Veldkamp
More informationLa terapia dell infezione da HIV: passato, presente e futuro.
1 st Infectivology Today Paestum (SA) 14-15 maggio 2004 La terapia dell infezione da HIV: passato, presente e futuro. Prof. Adriano Lazzarin Università Vita-Salute San Raffaele, Milano Scuola di Specializzazione
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationMaraviroc Pharmacokinetics in Blood Plasma, Genital Tract Fluid and Tissue in Healthy Female Volunteers
Maraviroc Pharmacokinetics in Blood Plasma, Genital Tract Fluid and Tissue in Healthy Female Volunteers Julie B. Dumond, Kristine B. Patterson, Allison Pecha, Rebecca E. Werner, Emma Andrews,* Bharat Damle,*
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 PREZISTA 400 mg, film-coated tablet B/60 (CIP code: 393 138-3) Applicant: JANSSEN-CILAG darunavir
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationGlobal Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2003, p. 350 359 Vol. 47, No. 1 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.1.350 359.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More informationToo small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants
Too small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants Mark Mirochnick, MD Boston University School of Medicine, Boston, MA, USA Full Term Full Term 34 wks
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationADM Kashuba, PharmD, Eshelman School of Pharmacy, UNC Chapel Hill
ADM Kashuba, PharmD, Eshelman School of Pharmacy, UNC Chapel Hill Stroma Is there an ARV target conc n to abort HIV infection in the stroma? Fauci A. WAC 2010 Monkey Plasma Concentration Relative to Human
More informationMedian (Min Max) CVC 100 mg + EFV placebo + TDF/FTC (N=8) CVC 200 mg + EFV placebo + TDF/FTC (N=10) LLOQ=5.00 ng/ml Time (h)
600 Pharmacokinetics (Pk) of cenicriviroc (cvc) following 100 or 200 mg once-daily Dosing with open-label tenofovir / emtricitabine (tdf/ftc) in hiv-1 infected subjects enrolled in a Phase 2b study David
More informationJennifer R King, Amit Khatri, Roger Trinh, Bifeng Ding, Jiuhong Zha and Rajeev Menon AbbVie Inc.
Pharmacokinetics of Darunavir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin in Adults Infected with Hepatitis C Virus (HCV) Genotype 1 and Human Immunodeficiency Virus (HIV) Jennifer R
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationPK-PD modelling to support go/no go decisions for a novel gp120 inhibitor
PK-PD modelling to support go/no go decisions for a novel gp120 inhibitor Phylinda LS Chan Pharmacometrics, Pfizer, UK EMA-EFPIA Modelling and Simulation Workshop BOS1 Pharmacometrics Global Clinical Pharmacology
More informationPharmacology of generics. Dario Cattaneo Unit of Clinical Pharmacology Luigi Sacco University Hospital, Milano, ITALY
Pharmacology of generics Dario Cattaneo Unit of Clinical Pharmacology Luigi Sacco University Hospital, Milano, ITALY Generics are effective drugs -Laurent, Lancet 2004 - that have improved access to therapy
More informationIndustry Data Request
Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,
More informationPediatric ARV Working Group Dosing Recommendations
Pediatric ARV Working Group Dosing Recommendations Overall Goals To develop pediatric weight band dosing for ARVs that would simplify dosing and produce therapeutic drug exposure Recommend dosing strengths
More informationDrug-Drug Interactions and the Pharmacotherapy of HIV Infection
International AIDS Society USA Topics in HIV Medicine Perspective Drug-Drug Interactions and the Pharmacotherapy of HIV Infection Angela D. M. Kashuba, PharmD Knowledge of drug-drug interactions is crucial
More informationDRUG INTERACTIONS WITH GRAZOPREVIR AND ELBASVIR
DRUG INTERACTIONS WITH GRAZOPREVIR AND ELBASVIR Pharmacology NS3/4A protease inhibitor NS5A inhibitor Adult Dose Investigational: 100 mg once daily Investigational: 50 mg once daily Being developed as
More informationWhen to start, when to switch ART and monitoring of ARV side effects
When to start, when to switch ART and monitoring of ARV side effects Thanomsak Anekthananon, MD Faculty of Medicine Siriraj Hospital September 4, 2009 Recommended Websites Free e-book: HIV Medicine 2007
More informationProtease Inhibitor Therapy: Boosted and Double-Boosted Options to the Fore
Protease Inhibitor Therapy: Boosted and Double-Boosted Options to the Fore Reprinted from The prn Notebook march 2004 Dr. James F. Braun, Editor-in-Chief Tim Horn, Executive Editor. Published in New York
More information#O-16: Darunavir and Ritonavir Total and Unbound Plasmatic Concentrations in HIV-HCV Coinfected Patients with Hepatic Cirrhosis
#O-16: Darunavir and Ritonavir Total and Unbound Plasmatic Concentrations in HIV-HCV Coinfected Patients with Hepatic Cirrhosis Adrian Curran 1, Ramon Marti 2, Rosa Maria Lopez 3, Mercè Perez 1, Eva van
More informationPharmacokinetics and Drug Interaction Profile of Cobicistat boosted-elvitegravir with Atazanavir, Rosuvastatin or Rifabutin
Pharmacokinetics and Drug Interaction Profile of Cobicistat boosted-elvitegravir with Atazanavir, Rosuvastatin or Rifabutin S Ramanathan, H Wang, T Stondell, A Cheng, and BP Kearney Gilead Sciences, Inc.,
More informationPK variability of antiretrovirals in the clinical setting: which lesson for clinicians?
PK variability of antiretrovirals in the clinical setting: which lesson for clinicians? Dario Cattaneo, PharmD, PhD Unit of Clinical Pharmacology Luigi Sacco University Hospital, Milano, ITALY My disclosures
More informationSELECTING THE BEST ART FOR EACH PATIENT
SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May
More informationNational AIDS Treatment Advocacy Project
National AIDS Treatment Advocacy Project Nelfinavir: general information, study results (CD4 and viral load), dosing schedule, eating instructions, drug interactions, combination with other protease inhibitors
More informationPediatric Patient Information:
New pediatric dosing information for Aptivus, patients 2-18 years of age, approval of New Oral Solution and information on coadministration with midazolam Aptivus (tipranavir) is now available as an oral
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/144040
More informationHIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
More informationDrug toxicities: Safest PIs. Michelle Moorhouse 14 Apr 2016
Drug toxicities: Safest PIs Michelle Moorhouse 14 Apr 2016 Impact of PIs on AIDS mortality CDC.gov. Epidemiology of HIV infection. Evolution of PIs http://www.clinicaloptions.com/hiv/treatment%20updates/boosted%20pis/interactive%20virtual%20presentation/slideset.aspx
More informationPaediatric ART Working Group. guideline review meetings
Paediatric ART Working Group Report back from Sept 2009 and Dec 2009 ART guideline review meetings Paediatric ARV working group priorities Continue to emphasise need for scored adult FDCs this avoids need
More informationPharmacokinetic-guided Antiretroviral Therapy. Chih-Hsun Tai, M.S., RPh. Department of Pharmacy National Taiwan University Hospital
Pharmacokinetic-guided Antiretroviral Therapy Chih-Hsun Tai, M.S., RPh. Department of Pharmacy National Taiwan University Hospital Introduction HAART allows a complete viral suppression But Not all patients
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationDarunavir STADA 400, 600 and 800 mg film-coated tablets , Version 1.1 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Darunavir STADA 400, 600 and 800 mg film-coated tablets 7.9.2016, Version 1.1 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Human
More informationHIV and TB coinfection: Updates. Awewura Kwara, MD, MPH &TM Associate Professor, Alpert Medical School of Brown University
HIV and TB coinfection: Updates Awewura Kwara, MD, MPH &TM Associate Professor, Alpert Medical School of Brown University Learning objectives Identify the optimal timing of antiretroviral therapy in patients
More informationPractical Scenarios Calculating doses for newborns. Karen Buckberry
Practical Scenarios Calculating doses for newborns Karen Buckberry Real Life Midwife phones you HIV+ mother in labour Needs you to tell Dr what meds to prescribe for baby What info do you need? Info needed
More informationDIVISION OF ANTIVIRAL DRUG PRODUCTS (HFD-530) MICROBIOLOGY REVIEW NDA:
Atazanavir (BMS-232632, ATV) Molecular Formula: C 38 H 52 N 6 O 7 H 2 SO 4 Molecular Weight: 704.9 Dosage Form(s): 100/150/200 mg capsule Route(s) of Administration: Oral Pharmacological Category: Indication(s):
More informationSummary of treatment benefits
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Human immunodeficiency virus (HIV) attacks the cells of the immune system, the body's natural defense against germs and other
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN Summary of Risk Management Plan for PREZISTA (Darunavir [TMC114]) This is a summary of the risk management plan (RMP) for PREZISTA. The RMP details important
More information